Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES) - 18/04/17
on behalf of the
international Vitiligo Score Working Group
Abstract |
Background |
The Vitiligo Extent Score (VES) has recently been introduced as a physicians' score for the clinical assessment of the extent of vitiligo, but a good patient self-assessment score is lacking.
Objective |
The objective is to develop and validate a simplified version of the VES as a patient-reported outcome measure (PROM).
Methods |
After extensive pilot testing, patients were asked to score their vitiligo extent twice with an interval of 2 weeks using the Self Assessment Vitiligo Extent Score (SA-VES). The scores were compared with the physicians' evaluation (VES).
Results |
The SA-VES demonstrated very good test-retest reliability (intraclass correlation = 0.948, 95% confidence interval [CI]: 0.911-0.970) that was not affected by age, skin type, or vitiligo distribution pattern. According to patients, this evaluation method was easy to use (22% very easy; 49% easy; 29% normal) and required <5 minutes in the majority of patients (73%, <5 minutes; 24%, 5-10 minutes; 2%, 10-15 minutes). Comparison of the SA-VES and the VES demonstrated excellent correlation (r = 0.986, P <.001).
Limitations |
Few patients had a dark skin type.
Conclusion |
The results demonstrate excellent reliability of the SA-VES and excellent correlation with its investigator-reported counterpart (VES). This patient-oriented evaluation method provides a useful tool for the assessment of vitiligo extent.
Le texte complet de cet article est disponible en PDF.Key words : body surface area, outcome measurement, patient-reported outcomes, severity, vitiligo
Abbreviations used : BSA, COSMIN, ICC, IQR, PROM, SA-VES, SDC, SEM, VASI, VES
Plan
Supported by the EADV (approved Project Proposal n°2015-030). The research activities of the principle investigator N. van Geel are supported by the Scientific Research Foundation-Flanders (FWO Senior Clinical Investigator: 1831512N) and of R. Speeckaert by postdoctoral research grant (01P12914) from the Ghent University Special Research Fund. |
|
Drs van Geel and Lommerts contributed equally. |
|
Conflicts of interest: None declared. |
Vol 76 - N° 3
P. 464-471 - mars 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?